Report #2835817

Overview

Sex

Unknown

Age

Age unknown

State

NC

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

it said that administer subcutaneously, we did one intramuscularly; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: it said that administer subcutaneously, we did one intramuscularly). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 03-APR-2025 It was reported for the MMR, Priorix vaccine, it said to administer subcutaneously, they did one intramuscularly which led to subcutaneous injection formulation administered by other route. The reporter wanted to know about the side effects or what happens, and asked If it is not effective.